Other languages Hepion Pharmaceuticals, Inc.

Equities

HEPA

US4268973025

Market Closed - Nasdaq Other stock markets 01:30:00 02/05/2024 am IST			5-day change	1st Jan Change
1.36 ^USD	-0.37%		+3.03%	-58.02%

22/04	Sector Update: Health Care Stocks Increase Late Afternoon	MT
22/04	Sector Update: Health Care	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Hepion Pharmaceuticals, Inc. Initiates Wind-Down Activities in Phase 2b ?ASCEND-NASH? Trial	20/04
Hepion Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	17/04
Hepion Pharmaceuticals, Inc. Appoints Michael Purcell to Its Board of Directors	06/03
Hepion Pharmaceuticals, Inc. Announces Board Changes	21/02
Hepion Pharmaceuticals, Inc. Announces Resignation of Anand Reddi from the Board of Directors	08/02
Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value	07/12
Hepion Pharmaceuticals Approves Restructuring Plan to Preserve Capital, Launches Strategic Review Process	07/12
Hepion Pharmaceuticals, Inc. Announces Resignation of Robert Foster as Director	07/12
Hepion Pharmaceuticals, Inc. Announces CEO Changes	07/12
Hepion Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	21/11
Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-Week Phase 2 Study of Advanced (F3) Mash Liver Disease	14/11
Hepion Pharmaceuticals, Inc. Announces the Publication of New Research Study in Mice	25/23/25
Hepion Pharmaceuticals, Inc. Announces Results from A Study with in Which the Anti-Cancer Activity of Hepion's Lead Drug Candidate, Rencofilstat	21/23/21
Aurinia Pharmaceuticals Appoints Robert Foster as Part of Deal With Shareholder MKT Capital	21/23/21
Hepion Pharmaceuticals Reports Novel Rencofilstat Action in Liver Cancer	19/23/19
Hepion Says Research Study on Idiopathic Pulmonary Fibrosis Involving Drug Candidate Rencofilstat Showed Positive Results	14/23/14
Hepion Pharmaceuticals, Inc. Announces Positive Results from Translational Research Study	14/23/14
Hepion Pharmaceuticals, Inc. Announces Resignation of Dr. Todd Hobbs, as the Chief Medical Officer, Effective September 29, 2023	07/23/07
Hepion Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/23/15
Hepion Pharmaceuticals Announces Passing of Key Safety Milestone in Phase 2b ‘ASCEND-NASH’ Trial of Rencofilstat	15/23/15

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Hepion Pharmaceuticals, Inc.

Equities

HEPA

US4268973025

Other languages

Filters